淋巴免疫治疗特应性皮炎30例疗效观察

发布时间：2018-06-26 10:12

本文选题：标准化过敏原 + 屋尘螨　；参考：《中国皮肤性病学杂志》2014年01期

【摘要】：目的探讨过敏原淋巴免疫治疗特应性皮炎的临床疗效和安全性。方法 60例对屋尘螨过敏的特应性皮炎患者,随机分为治疗组和对照组,每组各30例,对照组给予0.1%糠酸莫米松乳膏(Mometasone furoate cream)、1.2%维生素B_6软膏(Vitamin B_6 ointment)、氯雷他定片(Loratadine tablets)、富马酸酮替芬片(Ketotifen fumarate tablets)等基础药物治疗,治疗组在上述药物治疗的基础上,超声引导下分别于0周、4周、8周、12周、16周、20周行腹股沟淋巴结内注射屋尘螨过敏原制剂,除0周用药剂量为100SQ-U外,其余5次剂量均为1 000SQ-U。治疗前后两组患者分别行血清屋尘螨特异性免疫球蛋白E(sIgE)检测、特应性皮炎评分(SCORAD),用药评分,并记录患者疗程中的不良反应。结果治疗组患者治疗后4,8,12,16,20周SCORAD分别为(31.70±3.31)、(28.97±2.93)、(24.37±2.71)、(22.07±2.56)、(18.60±2.18),低于治疗前(0)周(33.03±4.92),差异有统计学意义(P0.01);12,16,20周SCORAD均低于对照组同时间SCORAD[(27.40±3.77)、(26.50±3.15)、(23.67±2.71)],差异有统计学意义(P0.01)。治疗组治疗后药物评分(1.61±0.98)和血清屋尘螨sIgE浓度(4.44±3.68)kU/L明显低于治疗前[(4.63±1.54)、(8.94±5.86)kU/L],且明显低于对照组[(2.42±0.60)、(7.88±4.50)kU/L],差异均有统计学意义(P0.01)。30例淋巴免疫治疗患者进行了180次浅表淋巴结注射,无局部不良反应和全身不良反应发生。结论过敏原淋巴免疫治疗特应性皮炎不仅临床疗效显著,而且大大缩短了疗程,减少了过敏原剂量、注射次数和不良反应的发生,为安全、有效的病因治疗方法。
[Abstract]:Objective to investigate the clinical efficacy and safety of allergic lymphoid immunotherapy for atopic dermatitis. Methods Sixty patients with atopic dermatitis allergic to house dust mite were randomly divided into treatment group (n = 30) and control group (n = 30). The control group was treated with 0.1% Mometasone furoate cream) 1.2% vitamin B6 ointment and other basic drugs such as ketotifen fumarate tablets). The treatment group was treated with basic drugs such as ketotifen fumarate tablets). Hypersensitive agents of house dust mites were injected into inguinal lymph nodes at 0 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks and 20 weeks, respectively. The other 5 doses were 1 000 SQ-U except 100 SQ-U at 0 weeks. Serum specific immunoglobulin E (Siga E), atopic dermatitis score (SCORAD), medication score and adverse reactions were recorded before and after treatment. Results the SCORAD in the treatment group was (31.70 卤3.31), (28.97 卤2.93), (28.97 卤2.93), (24.37 卤2.56), (22.07 卤2.56), (18.60 卤2.18), lower than that before treatment (33.03 卤4.92) weeks after treatment. The difference was statistically significant (P0.01). The SCORAD was significantly lower than that of the control group at the same time (27.40 卤3.77), (26.50 卤3.15), (23.67 卤2.71). After treatment, the drug score (1.61 卤0.98) and serum Siga (4.44 卤3.68) KU / L in the treatment group were significantly lower than those before the treatment [(4.63 卤1.54), (8.94 卤5.86) KUP / L] and significantly lower than that in the control group [(2.42 卤0.60), (7.88 卤4.50) KUP / L]. The difference was statistically significant (P0.01) .30 cases of lymphoid immunotherapy were injected with superficial lymph nodes. No local adverse reactions or systemic adverse reactions occurred. Conclusion the treatment of atopic dermatitis by immunotherapy with allergen lymphoid is not only effective, but also shortens the course of treatment, reduces the dose of allergen, the times of injection and the occurrence of adverse reactions. It is a safe and effective method for etiological treatment.
【作者单位】：郑州大学第一附属医院皮肤科;中国人民解放军第150中心医院变态反应中心;
【分类号】：R758.2

【共引文献】